Anchorage Capital Group, L.L.C. In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Anchorage Capital Group, L.L.C. reported 5 stock positions worth $239.9 million . Its top holding was Sentinelone Class A (S) at 37.4% of the portfolio, followed by Frontier Communications Pare (FYBR, 36.5% ) and Roivant Sciences (ROIV, 20.3% ). Its holdings were unchanged from Q4 2024.
Location NEW YORK, NY
CIK 0001300714
Portfolio Value $239.9M (Q1 2025) Holdings 5 stocks · $239.9M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q4 2024 S Sentinelone Inc. Class A 37.42% 4,937,053 $89.8M No change FYBR Frontier Communications Pare 36.53% 2,443,742 $87.6M No change ROIV Roivant Sciences Ltd. 20.33% 4,832,642 $48.8M No change DNA Ginkgo Bioworks Holdings Inc. 4.15% 1,746,363 $10.0M No change AMBP Ardagh Metal Packaging SA 1.57% 1,250,000 $3.8M No change
Other holdings (2): bonds, preferreds, convertibles and warrants · $10.2M (not counted above) Security Class Shares / Principal Value Change THE REALREAL INC (REAL 4 02/15/31) DEBT 4.000% 2/1 · principal 12,077,000 $10.2M New AMPWF Ardagh Metal Packaging -CW26 *W EXP 08/04/202 1,245,385 $23K No change
Total filed on the 13F, all lines: $250.1M.
Portfolio Sells Q4 2024 → Q1 2025 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2024 % Of Portfolio Change To Portfolio ▲ None this quarter.
Portfolio Buys Q4 2024 → Q1 2025 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2024 % Of Portfolio Change To Portfolio ▼ None this quarter.
Notes & Other Activity Q4 2024 → Q1 2025 Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 3 $450.5M EQPT, S, DNA Q1 2026 3 $436.3M EQPT, S, DNA Q4 2025 2 $88.6M S, DNA Q3 2025 3 $117.4M S, DNA, AMBP Q2 2025 5 $258.7M S, FYBR, ROIV, DNA, AMBP Q1 2025 5 $239.9M S, FYBR, ROIV, DNA, AMBP Q4 2024 5 $272.5M S, FYBR, ROIV, DNA, AMBP Q3 2024 5 $374.8M FYBR, S, ROIV, DNA, AMBP Q2 2024 5 $316.7M FYBR, S, ROIV, DNA, AMBP Q1 2024 6 $377.5M FYBR, S, DNA, ROIV, AMBP